2022 TIME TRIAL Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK prospective, open-label, blinded-endpoint, randomized controlled trial IM Objective: To compare the major cardiovascular outcomes of evening dosing of antihypertensive medication versus morning dosing in patients with hypertension treated with their usual antihypertensive medications 21104 patients Inclusion criteria: Patients ≥18 years, UK residents with hypertension, and taking ≥1 antihypertensive medication daily 3.4 VS ههتة Evening dosing (n=10,503) Morning dosing (n=10,601) PRIMARY OUTCOME Cardiovascular endpoint of vascular death or hospitalization for non-fatal MI or non-fatal stroke % HR 0.65; 95% CI, 0.38 to 1.09; P = 0.09 SECONDARY OUTCOMES 3.7 4.2 All-cause death % 4.1 HR 1.04; 95% CI, 0.91 to 1.18; P = 0.59 Hospitalization or death from congestive 0.7 heart failure % 0.9 HR 0.79; 95% CI, 0.59 to 1.07; P=0.12 Conclusion: Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Prof IS Mackenzie et al. Lancet 2022;400(10361):1417-1425